SLS BIO Co., Ltd (KOSDAQ:246250)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,969.00
+85.00 (4.51%)
At close: Jun 9, 2025

SLS BIO Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2015
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '15
Revenue
3,1873,9848,3719,02310,7526,214
Revenue Growth
-60.55%-52.41%-7.23%-16.08%73.02%6.75%
Gross Profit
-2,752-1,9372,2693,1114,2101,363
Operating Income
-4,836-4,105287.621,0312,424522.53
Net Income
-5,644-4,904335.631,4342,826204.47
Earnings Per Share
-375.08-325.8822.00102.00412.0041.00
EPS Growth
---78.43%-75.24%904.88%-44.59%

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2015
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '15
Cash & Investments
2,2743,3247,6809,3552,5481,966
Total Debt
1,1621,3141,7102,1052,5174,111
Net Cash (Debt)
1,1122,0105,9707,25030.98-2,144
Net Cash Growth
-81.69%-66.33%-17.66%23304.74%--
Net Cash Per Share
73.87133.60391.34515.694.52-430.00

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2015
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '15
Operating Cash Flow
-3,187-2,1951,7263,4364,034724.79
Capital Expenditures
-1,549-1,514-1,456-1,274-719.23-627.13
Free Cash Flow
-4,736-3,709269.922,1623,31597.66
Free Cash Flow Growth
---87.51%-34.79%3294.14%-88.45%

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2015
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '15
Gross Margin
-86.35%-48.63%27.10%34.48%39.16%21.93%
Operating Margin
-151.75%-103.05%3.44%11.43%22.54%8.41%
Pretax Margin
-191.96%-135.04%4.23%11.72%20.69%3.18%
Profit Margin
-177.10%-123.09%4.01%15.89%26.28%3.29%
FCF Margin
-148.62%-93.09%3.22%23.96%30.83%1.57%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2015
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '15
PE Ratio
--78.3324.5712.02-
P/FCF Ratio
--97.3916.3010.25-
PS Ratio
8.446.753.143.913.16-